This publication strengthens ILUVIEN’s clinical profile but does not represent regulatory or commercial progress. Traders should monitor for future sales trends in ophthalmology, but no immediate revenue inflection is implied. The recent insider selling trend warrants caution on sentiment.
Price Chart
Executive Summary
ANI Pharmaceuticals announced the publication of NEW DAY clinical trial results for ILUVIEN in the journal Ophthalmology, reinforcing clinical data for its use in diabetic macular edema (DME). This is a scientific validation rather than a new clinical or commercial development.
Key Facts
- Results from the NEW DAY Phase 4 trial of ILUVIEN for diabetic macular edema were published in Ophthalmology, a peer-reviewed journal.
- The trial results were previously disclosed in July 2025; this press release highlights peer-reviewed publication.
- ILUVIEN is indicated for DME patients previously treated with corticosteroids without significant intraocular pressure rise.
- Safety data show high incidence of cataract (82%), intraocular pressure elevation (34% had ≥10 mm Hg increase), and need for IOP-lowering treatment (38%).
Financial Impact
Minimal near-term financial impact; publication supports long-term clinical credibility but does not expand indications or drive immediate sales growth.
Risk Factors
- High rate of cataract formation and IOP elevation may limit adoption despite efficacy.
- Ongoing competition from anti-VEGF therapies for DME could constrain market penetration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268938 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $72.11 $77.91 | ▲ +8.04% | ▲ +7.23% | $71.97 (−0.19%) |
Sep 1, 2026 4w ago | Insider Cluster | $73.06 $71.46 | ▼ −2.19% | ▼ −1.23% | $71.97 (−1.49%) |
Aug 24, 2026 5w ago | 8-K | $74.17 $73.25 | ▼ −1.24% | ▼ −1.71% | $71.97 (−2.97%) |
Aug 13, 2026 7w ago | Insider Cluster | $74.77 $77.32 | ▲ +3.41% | ▲ +5.37% | $71.97 (−3.74%) |
Aug 7, 2026 8w ago | 8-K | $78.25 $76.54 | ▼ −2.19% | ▼ −2.58% | $71.97 (−8.03%) |
Jul 16, 2026 11w ago | Court Ruling | $81.92 $78.53 | ▼ −4.14% | ▼ −2.47% | $71.97 (−12.15%) |
Jul 13, 2026 11w ago | Press Release | $81.08 $79.20 | ▼ −2.32% | ▼ −1.53% | $71.97 (−11.24%) |
Jun 15, 2026 15w ago | Insider Cluster | $83.00 $82.94 | ▼ −0.07% | ▲ +2.16% | $71.97 (−13.29%) |
Jun 11, 2026 16w ago | Insider Cluster | $81.65 $80.52 | ▼ −1.38% | ▼ −1.82% | $71.97 (−11.86%) |
May 21, 2026 19w ago | 8-K | $82.72 $76.71 | ▼ −7.27% | ▼ −8.92% | $71.97 (−13.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access